New hope for Tough-to-Treat lung cancer: experimental combo targets tumors two ways
NCT ID NCT07388875
Summary
This study is testing whether combining two drugs, sacituzumab tirumotecan and anlotinib, can help control advanced small cell lung cancer in patients whose cancer has worsened after their initial immunotherapy and chemotherapy treatment. The trial will enroll about 30 adults to see if this combination can shrink tumors and extend life. Researchers hope the two drugs will work together to attack cancer cells more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.